Biogen Shares Spike on Alzheimer's Update
The first new drug application for an experimental therapy meant to prevent Alzheimer's disease from worsening finally reached regulators on Wednesday. Biogen (NASDAQ: BIIB) has finally submitted a biologics license application (BLA) for aducanumab, a monthly infusion that prevents amyloid plaques from forming in the brain.
The company's requested a shortened six-month review instead of the usual 10-month process. The Food and Drug Administration has 60 days to let Biogen know if it will review the aducanumab BLA in any form.
As of 3:35 p.m. EDT today, Biogen shares were up just over 4.2%.
Source Fool.com
